Literature DB >> 25684748

The relation between α-synuclein and microglia in Parkinson's disease: Recent developments.

V Sanchez-Guajardo1, N Tentillier2, M Romero-Ramos3.   

Abstract

Recent research suggests a complex role for microglia not only in Parkinson's disease but in other disorders involving alpha-synuclein aggregation, such as multiple system atrophy. In these neurodegenerative processes, the activation of microglia is a common pathological finding, which disturbs the homeostasis of the neuronal environment otherwise maintained, among others, by microglia. The term activation comprises any deviation from what otherwise is considered normal microglia status, including cellular abundance, morphology or protein expression. The microglial response during disease will sustain survival or otherwise promote cell degeneration. The novel concepts of alpha-synuclein being released and uptaken by neighboring cells, and their importance in disease progression, positions microglia as the main cell that can clear and handle alpha-synuclein efficiently. Microglia's behavior will therefore be a determinant on the disease's progression. For this reason we believe that the better understanding of microglia's response to alpha-synuclein pathological accumulation across brain areas and disease stages is essential to develop novel therapeutic tools for Parkinson's disease and other alpha-synucleinopathies. In this review we will revise the most recent findings and developments with regard to alpha-synuclein and microglia in Parkinson's disease.
Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Parkinson’s disease; TLR; alpha-synuclein; microglia; neuroinflammation

Mesh:

Substances:

Year:  2015        PMID: 25684748     DOI: 10.1016/j.neuroscience.2015.02.008

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  77 in total

1.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Authors:  Erin M Hill-Burns; Justine W Debelius; James T Morton; William T Wissemann; Matthew R Lewis; Zachary D Wallen; Shyamal D Peddada; Stewart A Factor; Eric Molho; Cyrus P Zabetian; Rob Knight; Haydeh Payami
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

2.  Spinal cord injury and Parkinson's disease: a population-based, propensity score-matched, longitudinal follow-up study.

Authors:  T-S Yeh; Y-P Huang; H-I Wang; S-L Pan
Journal:  Spinal Cord       Date:  2016-05-31       Impact factor: 2.772

3.  Lipopolysaccharide-Induced Microglial Neuroinflammation: Attenuation by FK866.

Authors:  Yaling Xu; Lijia Yu; Ying Liu; Xiaohui Tang; Xijin Wang
Journal:  Neurochem Res       Date:  2021-03-13       Impact factor: 3.996

Review 4.  iPS cells in the study of PD molecular pathogenesis.

Authors:  Melanie M Cobb; Abinaya Ravisankar; Gaia Skibinski; Steven Finkbeiner
Journal:  Cell Tissue Res       Date:  2017-12-12       Impact factor: 5.249

5.  Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes.

Authors:  Lei Xia; Dianxuan Guo; Bing Chen
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

6.  Motor Neurons Pathology After Chronic Exposure to MPTP in Mice.

Authors:  Giorgio Vivacqua; Francesca Biagioni; Carla L Busceti; Michela Ferrucci; Michele Madonna; Larisa Ryskalin; Shun Yu; Loredana D'Este; Francesco Fornai
Journal:  Neurotox Res       Date:  2019-11-13       Impact factor: 3.911

7.  Protective effects of Astragaloside IV against oxidative injury and apoptosis in cultured astrocytes by regulating Nrf2/JNK signaling.

Authors:  Jintao Yang; Chongyu Shao; Wentao Li; Haitong Wan; Yu He; Jiehong Yang
Journal:  Exp Brain Res       Date:  2021-04-08       Impact factor: 1.972

Review 8.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

9.  Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.

Authors:  Hongwei Qin; Jessica A Buckley; Xinru Li; Yudong Liu; Thomas H Fox; Gordon P Meares; Hao Yu; Zhaoqi Yan; Ashley S Harms; Yufeng Li; David G Standaert; Etty N Benveniste
Journal:  J Neurosci       Date:  2016-05-04       Impact factor: 6.167

Review 10.  Multiple system atrophy: experimental models and reality.

Authors:  Cassia Overk; Edward Rockenstein; Elvira Valera; Nadia Stefanova; Gregor Wenning; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2017-10-20       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.